Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide (Journal of Clinical Sleep Medicine, (2026), 22, 1, (35), 10.1007/s44470-025-00024-0)
Issued Date
2026-12-01
Resource Type
ISSN
15509389
eISSN
15509397
Scopus ID
2-s2.0-105039570032
Pubmed ID
42151574
Journal Title
Journal of Clinical Sleep Medicine
Volume
22
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Sleep Medicine Vol.22 No.1 (2026)
Suggested Citation
Schmickl C.N., Tripipitsiriwat A., Mokhlesi B., Mallampalli M., Nokes B., Kundel V., Page K., Finch C., Donovan L., Tadros M., Aysola R.S., Zinchuk A., Zvenyach T., Badr M.S., Patel S.R., Orr J.E., Owens R.L., Lindsell C., Martin J.L., Malhotra A. Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide (Journal of Clinical Sleep Medicine, (2026), 22, 1, (35), 10.1007/s44470-025-00024-0). Journal of Clinical Sleep Medicine Vol.22 No.1 (2026). doi:10.1007/s44470-026-00074-y Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/117009
Title
Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide (Journal of Clinical Sleep Medicine, (2026), 22, 1, (35), 10.1007/s44470-025-00024-0)
Author's Affiliation
University of California, Los Angeles
University of California, San Diego
University of Pittsburgh
Yale University
David Geffen School of Medicine at UCLA
University of Washington School of Medicine
Icahn School of Medicine at Mount Sinai
Duke University School of Medicine
Wayne State University School of Medicine
Rush University Medical Center
Siriraj Hospital
VA Greater Los Angeles Healthcare System
Obesity Action Coalition
Alliance for Sleep Apnea Partners (ASAP)
Patient Representative
University of California, San Diego
University of Pittsburgh
Yale University
David Geffen School of Medicine at UCLA
University of Washington School of Medicine
Icahn School of Medicine at Mount Sinai
Duke University School of Medicine
Wayne State University School of Medicine
Rush University Medical Center
Siriraj Hospital
VA Greater Los Angeles Healthcare System
Obesity Action Coalition
Alliance for Sleep Apnea Partners (ASAP)
Patient Representative
Corresponding Author(s)
Other Contributor(s)
Abstract
The original online version of this article was revised to update Figures 1, 2, 3, 4 and adjust the presentation of Table 2. (Figure presented.) (Figure presented.) (Figure presented.) (Figure presented.) (Table presented.) Timeline of outreach activities and survey completions US survey responses by state. 98% (452) of participating patients and 86% (98) of providers reported their primary residence to be in the United States. Among those, patient responses were concentrated in California (Panel A), whereas provider responses were more broadly distributed across US regions (Panel B) Treatment acceptability and preferences. If you had (a patient with) newly diagnosed, untreated COBOSA, how acceptable would you find it to use/prescribe CPAP (Panel A) or tirzepatide (Panel B). If there was strong evidence that both Tirzepatide and CPAP treat sleep apnea and associated risks/symptoms similarly well, which one would you prefer long-term? (Panel C). If there was strong evidence that combining both CPAP + Tirzepatide leads to greater improvements of sleep apnea and associated risks/symptoms than using either CPAP or tirzepatide alone, would you be willing to use/prescribe both of them together long-term? (Panel D). Provider responses are green, non-provider (i.e., patients) responses are purple. Response patterns differed significantly between patients and providers across all four assessments (Fisher’s exact test, P <.001). Bars reflect 95% confidence intervals. PNTS Prefer not to say Information patients (n = 440) and providers (n = 104) need for decision making Patients only: clinical characteristics and history Characteristic Patients N = 461<sup>1</sup> Body mass index (BMI), kg/m<sup>2</sup> 31 (27, 35) Overweight (BMI 25–30 kg/m<sup>2</sup>) 155 (34%) Obesity (BMI > 30 kg/m<sup>2</sup>) 247 (54%) Likely OSA (diagnosis or STOP score<sup>2</sup>≥ 2) OSA diagnosis, yes vs. no/unsure 398 (86%) COBOSA (OSA diagnosis + obesity) 224 (49%) Hypertension 231 (50%) Diabetes 72 (16%) Mood disorder 177 (38%) If yes, does snoring disrupt your relationships? 209 (79%) 1+/week 298 (65%) < 1/week 156 (34%) Unsure/PNTS 7 (1.5%) 1+/week 316 (69%) < 1/week 141 (31%) Unsure/PNTS 4 (0.9%) 1+/week 302 (66%) < 1/week 153 (33%) Unsure/PNTS 6 (1.3%) 1+/week 214 (46%) < 1/week 228 (49%) Unsure/PNTS 19 (4.1%) Currently 285 (78%) In the past 70 (19%) Never 9 (2.5%) Unsure/PNTS 2 (0.5%) Currently 36 (9.8%) In the past 41 (11%) Never 281 (77%) Unsure/PNTS 8 (2.2%) Currently 6 (1.6%) In the past 4 (1.1%) Never 348 348 (95%) Unsure/PNTS 8 (2.2%) Yes 24 (6.6%) No 332 (91%) Unsure/PNTS 10 (2.7%) Among those using CPAP/OAT/HNS currently (n= 315<sup>3</sup>) – therapy use on average > 4 h/night during past month Never 30 (6.5%) 1–2 times 80 (17%) 3–5 times 88 (19%) > 5 times 250 (54%) Unsure/PNTS 13 (2.8%) Currently 33 (24%) In the past 69 (50%) Never 34 (25%) Unsure/PNTS 2 (1.4%) Currently 20 (14%) In the past 43 (31%) Never 67 (49%) Unsure/PNTS 8 (5.8%) Never 36 (26%) Unsure/PNTS 5 (3.6%) Currently/In the past 97 (70%) Currently 31 (32%) In the past 8 (8.2%) Never 57 (59%) Unsure/PNTS 1 (1.0%) Currently 50 (52%) In the past 21 (22%) Never 26 (27%) Unsure/PNTS 0 (0%) Currently 1 (1.0%) In the past 7 (7.2%) Never 88 (91%) Unsure/PNTS 1 (1.0%) Yes 23 (17%) No 112 (81%) Unsure/PNTS 3 (2.2%) <sup>1</sup>n (%); Median (Q1, Q3) <sup>2</sup>The STOP score consists of four yes/no questions, with one point assigned for each “yes” response. A total score of 2 or more indicates high risk for OSA [53]. The questions assess whether the individual: snores loudly; often feels tired, fatigued, or sleepy during the daytime; has been observed to stop breathing during sleep; or has (or is being treated for) high blood pressure <sup>3</sup>Of 327 participants who reported current usage of CPAP, OAT or HGNS, 11 report using currently both CPAP + OAT, and 1 reported using currently both CPAP + HGNS; 315 reported using CPAP, OAT, or HGNS as single therapy The original article has been corrected.